- Report
- October 2024
- 197 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- March 2025
- 194 Pages
Global
From €4706EUR$4,950USD£3,953GBP
- Report
- May 2024
- 171 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1188EUR$1,250USD£998GBP
- Drug Pipelines
- April 2024
- 60 Pages
Global
From €1901EUR$2,000USD£1,597GBP
- Report
- May 2024
- 134 Pages
Global
From €6178EUR$6,499USD£5,190GBP
- Report
- June 2024
- 200 Pages
Global
From €7558EUR$7,950USD£6,349GBP
- Report
- June 2024
- 200 Pages
Global
From €7558EUR$7,950USD£6,349GBP
- Report
- June 2024
- 200 Pages
Global
From €7558EUR$7,950USD£6,349GBP
- Report
- January 2022
- 60 Pages
Global
From €3755EUR$3,950USD£3,155GBP
- Report
- January 2022
- 60 Pages
Global
From €3755EUR$3,950USD£3,155GBP
- Report
- January 2022
- 111 Pages
Global
From €4516EUR$4,750USD£3,794GBP
- Report
- April 2024
- 95 Pages
Global
From €3500EUR$3,944USD£3,043GBP

The Fistula Drug market is a subset of the Gastrointestinal Drugs market, which includes drugs used to treat diseases and disorders of the digestive system. Fistula Drugs are used to treat fistulas, which are abnormal connections between two organs or between an organ and the skin. These drugs are used to reduce inflammation, reduce pain, and promote healing. Commonly used Fistula Drugs include corticosteroids, antibiotics, and immunosuppressants.
Fistula Drugs are typically administered orally, intravenously, or topically. The market for Fistula Drugs is expected to grow due to the increasing prevalence of fistulas and the need for effective treatments.
Some companies in the Fistula Drug market include AbbVie, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Merck, Novartis, Pfizer, and Sanofi. Show Less Read more